CGEM vs USB · $830.3M cap vs P/E 12, rev $28.66B
Cullinan Oncology LLC (CGEM) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Cullinan Oncology LLC (CGEM) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported CGEM revenue for 2022-12-31 was $0. Net income was $109.2M. CGEM currently screens at market cap $830.3M.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
CGEM currently screens at market cap $830.3M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the CGEM and USB stock pages for the full models.
Not investment advice.